BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:tovecimig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of tovecimig\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06548412-10870@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:tovecimig: Phase 1/2 readout est. (NCT06548412)
DESCRIPTION:tovecimig\, phase 1/2\, Biliary Tract Cancer.\nStudy: CTX-009 W
 ith Gemcitabine\, Cisplatin\, and Durvalumab as First-line Therapy in Pati
 ents With Unresectable or Metastatic Biliary Tract Cancers\nEstimated prim
 ary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tovecimig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06548412
URL:https://assetmemo.bio/drug/tovecimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05506943-10870@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:tovecimig: Phase 2/3 readout est. (NCT05506943)
DESCRIPTION:tovecimig\, phase 2/3\, Biliary Tract Cancer.\nStudy: A Study o
 f CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectab
 le Advanced\, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002
 )\nEstimated primary completion: 31 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tovecimig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05506943
URL:https://assetmemo.bio/drug/tovecimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392957-10870@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:tovecimig: Phase 1/2 readout est. (NCT07392957)
DESCRIPTION:tovecimig\, phase 1/2.\nStudy: Safety and Efficacy of CTX-009 W
 ith or Without CTX-471 for Recurrent Glioblastoma\nEstimated primary compl
 etion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tovecimig#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07392957
URL:https://assetmemo.bio/drug/tovecimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662031-10870@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:tovecimig: Phase 2 readout est. (NCT07662031)
DESCRIPTION:tovecimig\, phase 2.\nStudy: Tovecimig Plus FOLFIRI in Second L
 ine Metastatic Colorectal Cancer\nEstimated primary completion: 31 Decembe
 r 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/tovecimig#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0766203
 1
URL:https://assetmemo.bio/drug/tovecimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
